Cancer immunotherapy: breaking the barriers to harvest the crop
D Pardoll, J Allison - Nature medicine, 2004 - nature.com
D Pardoll, J Allison
Nature medicine, 2004•nature.comSuccessful translation of modern molecular immunology into effective cancer
immunotherapy is threatened by regulatory barriers and challenges to the development of
novel agents and combinatorial strategies through effective public-private partnerships. For
its promise to be fully realized, both the National Cancer Institute and Food and Drug
Administration must take active steps to help academic investigators and companies jointly
navigate the pathways from laboratory to clinic.
immunotherapy is threatened by regulatory barriers and challenges to the development of
novel agents and combinatorial strategies through effective public-private partnerships. For
its promise to be fully realized, both the National Cancer Institute and Food and Drug
Administration must take active steps to help academic investigators and companies jointly
navigate the pathways from laboratory to clinic.
Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.
nature.com